World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT04139018
Date of registration: 23/10/2019
Prospective Registration: No
Primary sponsor: Washington University School of Medicine
Public title: Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia ETIC-HHT
Scientific title: Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial
Date of first enrolment: October 20, 2019
Target sample size: 30
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT04139018
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Andrew M Peterson
Address: 
Telephone: 314-747-0910
Email: apeterson22@wustl.edu
Affiliation: 
Name:     Andrew M. Peterson
Address: 
Telephone: 314-747-0910
Email: apeterson22@wustl.edu
Affiliation: 
Name:     Jay F Piccirillo, MD
Address: 
Telephone:
Email:
Affiliation:  Washington University School of Medicine
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Adults ages 20 and older

2. Confirmed clinical (meeting at least 3 of the 4 Curaçao Criteria) or genetic diagnosis
of HHT

3. Epistaxis Severity Score (ESS) = 4 and 2 or more nosebleeds per week with a cumulative
nosebleed duration of at least 5 minutes per week

4. Stable nasal hygiene and medical regimen for preceding 1 month

5. Stable epistaxis pattern over the preceding 3 months

Exclusion Criteria:

1. Contraindications for systemic ß adrenergic blocker administration

1. Hypersensitivity to ß adrenergic blockers

2. Asthma or bronchospasm

3. Congestive heart failure with LVEF <40%

4. Hereditary pulmonary arterial hypertension

5. Baseline bradycardia (HR <55 beats per minute)

6. Sick Sinus Syndrome

7. 2nd or 3rd degree heart block, left or right bundle branch block, or bifasicular
block

8. Uncontrolled diabetes mellitus (most recent HbA1c >9%) or diabetic ketoacidosis
within last 6 months

9. Hypotension (systolic blood pressure < 90)

2. Known hypersensitivity to timolol

3. Severe peripheral circulatory disturbances (Raynaud phenomenon)

4. Known intermediate or poor metabolizer variant of the liver enzyme CYP2D6

5. Current use of any of the following known strong CYP2D6 inhibitors: fluoxetine
(Prozac), paroxetine (Paxil), bupropion (Welbutrin), quinidine, quinine, ritonavir
(Norvir), and terbinafine (Lamisil)

6. Current use of the following other drugs known to pharmacodynamically interact with
timolol: diltiazem, verapamil, digoxin, digitalis, propafenone, disopyramide,
clonidine, flecainide, or lidocaine

7. Patients currently treated or who plan to initiate treatment with ß-blockers

8. Use of any anti-angiogenic medication in the last month prior to recruitment,
including bevacizumab, pazopanib, thalidomide, or lenalidomide

9. Illicit drug use, except marijuana

10. Known pheochromocytoma

11. Use of anticoagulants, antiplatelet, or fibrinolytic therapies within the last month
prior to recruitment, except for low-dose (81 mg or less) of aspirin

12. Pregnancy or planned pregnancy in the next 6 months or currently breastfeeding

13. Inability to read or understand English

14. Inability to complete 8 weeks of therapy for any reason



Age minimum: 20 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Hereditary Hemorrhagic Telangiectasia
Intervention(s)
Drug: Placebo Gel
Drug: Timolol Gel
Primary Outcome(s)
Epistaxis Severity Scale [Time Frame: Baseline to 8-week follow-up]
Secondary Outcome(s)
HHT endoscopic scale (HES) [Time Frame: Baseline to 8-week follow-up]
Mean Change in Hemoglobin [Time Frame: Baseline to 8-week follow-up]
Clinical Global Impression - Improvement (CGI-I) Score [Time Frame: Baseline to 8-week follow-up]
Secondary ID(s)
201908160
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history